RXO, Inc. has officially entered into a merger agreement with C.H. Robinson Worldwide, Inc., a move that signifies a major consolidation in the transportation services industry. This merger is poised to enhance operational efficiencies and expand market reach for both companies, with RXO's shareholders now facing a choice between cash and stock options in the new entity.

The merger agreement was filed on October 5, 2026, and is expected to close in the first half of 2027, pending necessary approvals. The board of directors for both RXO and C.H. Robinson have unanimously approved the agreement, highlighting its strategic importance for the companies involved.

Background

RXO, Inc. operates within the transportation services sector, as classified under SIC 4700. The company was previously known as RXO, LLC, before changing its name in July 2022. RXO is traded on the New York Stock Exchange under the ticker symbol RXO.

What the Filing Says

According to the SEC filing (accession number 0001140361-26-038548), RXO has entered into an Agreement and Plan of Merger with C.H. Robinson. The agreement outlines that RXO will merge with a wholly owned subsidiary of C.H. Robinson, with RXO continuing as the surviving corporation. Following this, RXO will merge into Viking Logistics LLC, which will become the new surviving entity.

The RXO board has determined that the terms of the merger are fair and in the best interests of its shareholders. The filing states, "the RXO Board has unanimously... declared it advisable to enter into the Merger Agreement."

Impact

This merger will have significant implications for RXO's shareholders, who will receive either cash or stock in C.H. Robinson upon the merger's completion. The transaction is designed to qualify as a reorganization under the Internal Revenue Code, which may provide tax benefits to the shareholders. Additionally, the merger is expected to streamline operations and enhance service offerings in the transportation services sector.

What's Next

The merger is subject to customary closing conditions, including shareholder approval from RXO and regulatory clearances under antitrust laws. The filing does not specify the exact timeline for these approvals, but the transaction is anticipated to close in the first half of 2027.